Methods of improving myocardial performance in Fontan patients using udenafil compositions
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation.
1. A method of treating a single ventricle heart disease (SVHD) patient with udenafil, or a pharmaceutically acceptable salt thereof, to improve the SVHD patient's exercise capacity at both the patient's VO 2 max and anaerobic threshold, wherein the SVHD patient has undergone Fontan palliation, said method comprising:
administering to the SVHD patient an effective daily dose of udenafil, or a pharmaceutically acceptable salt thereof, to treat the SVHD patient to improve the SVHD patient's exercise capacity at both VO 2 max and the anaerobic threshold,
wherein the udenafil, or a pharmaceutically acceptable salt thereof, is administered in a total daily dose of about 175 mg of udenafil, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the udenafil, or a pharmaceutically acceptable salt thereof, is formulated as an oral dosage form.
3. The method of claim 2 , wherein the oral dosage form is a solid or semi-solid oral dosage form selected from a group of solid or semi-solid oral dosage forms consisting of a tablet, a capsule, a gel, a liquid dispersion, a pill, a powder, and a suspension.
4. The method of claim 2 , wherein the oral dosage form is a tablet.
5. The method of claim 2 , wherein the oral dosage form comprises about 87.5 mg of udenafil or a pharmaceutically acceptable salt thereof, and
wherein the method comprises orally administering the oral dosage form to the SVHD patient twice daily.
6. The method of claim 1 , wherein the SVHD patient is between about 12 years old and about 18 years old.
7. The method of claim 6 , wherein the udenafil, or a pharmaceutically acceptable salt thereof, is formulated as an oral dosage form.
8. The method of claim 7 , wherein the oral dosage form is a solid or semi-solid oral dosage form selected from a group of solid or semi-solid oral dosage forms consisting of a tablet, a capsule, a gel, a liquid dispersion, a pill, a powder, and a suspension.
9. The method of claim 7 , wherein the oral dosage form is a tablet.
10. The method of claim 7 , wherein the oral dosage form comprises about 87.5 mg of udenafil, or a pharmaceutically acceptable salt thereof, and
wherein the method comprises orally administering the oral dosage form to the SVHD patient twice daily.